EP Vantage
EP Vantage
Stop FollowingEP Vantage
View as an RSS Feed
View EP Vantage's Articles BY TICKER:
ABII,
ABT,
AFFY,
ALIM,
ALIOF.PK,
ALNY,
ALTH,
ALXN,
AMGN,
ARIA,
ARQL,
ASTM,
AZN,
BAX,
BCRX,
BMTI,
BMY,
BSNRF.PK,
BSX,
CADX,
CBST,
CELG,
CEPH,
CHTP,
CORT,
COV,
CYPB,
CYTK,
DDSS,
DEPO,
DMYDF.PK,
DNDN,
ECYT,
ESALY.PK,
EW,
FOLD,
FRX,
GE,
GILD,
GSK,
GTXI,
HALO,
HEB,
IMGN,
INHX,
ISPH,
ISTA,
ITMN,
JAZZ,
JNJ,
KG,
LLY,
LMNX,
MDCO,
MDT,
MDVN,
MEDX,
MKGAF.PK,
MNKD,
MYGN,
NAVB,
NEUSF.PK,
NVS,
NYMX,
OMER,
ONXX,
OPOSF.PK,
PARD.PK,
PCYC,
PFE,
PPHM,
RHHBY.OB,
RIGL,
SCR,
SNN,
SNY,
STJ,
SVNT,
SXMDF.PK,
TEVA,
THRX,
TMO,
UCBJY.PK,
UTHR,
VPHM,
VRX,
VVUS,
WILLF.PK,
WMGI,
YMI
- Optos Blindsides Investors With Big Profit Drop
- Biosensors Expands Its Horizons With Imaging Buy
- Lead Situation Improves For St. Jude, But The Future Could Be Wireless
- Covidien Aiming For Mallinckrodt Spin-Out
- Biotech Bulls Can Ignore The Warning Signs At Their Peril
- Diabetes Risk Sharing Moves Up A Gear
- Sirtex's Tiny Beads Could See Great Success In Liver Cancer
- Clean Superiority Sweep For Dulaglutide Could Reshape Diabetes Market
- Thermo Fisher Spends $14 Billion To Finally Get A Life
- Panel Backing For Lens Rewards Bausch & Lomb's Focus On Devices
- EP Vantage Interview - Bind Boosted By 2 Nanomedicine Deals
- William Demant Moves Into Fast Growing Cochlear Implant Sector
- Aubagio EU Backing Comes With Generic Worries
- No Quick Fixes, But Astra's Soriot Can Still Be Bold
- Navidea Takes A Kicking Despite Lymphoseek Approval
- Private Bid Brings Simcere And Chinese Speculation Down A Peg
- Engager CE Mark Inflames Competition Between Medtronic And Edwards
- Abbott Hopes Mitral Repair Will Be The New TAVI
- T-DM1 Approval Benefits Technology More Than It Does ImmunoGen
- Regulators Await Gilead's Hep C Candidate
- Amicus: Trial Detail Fails To Halt Share Slide
- Failure Of Nobori Trial Raises Questions For Dissolving-Polymer Stent Rivals
- Medicines Company Braces For 2015 With Alnylam PCSK9 Deal
- J&J Considers Diagnostics Sale, But Why Stop There?
- Luminex's 5-Hour Gastroenteritis Test Impresses FDA
- Latest Tivantinib Failure Hits ArQule Despite Its Irrelevance
- GE Healthcare Aims For Twofer With Alzheimer's Tracer Flutemetamol
- Now You See It, Now You Don't: Peregrine's Bavi Might Work After All
- Medtech News Over The Christmas Period
- Ariad Passes Its 12-Month Check-Up
- Investors Kick Chelsea After It Trips On Its Northera Data Again
- BioCryst Investors Breathe Sight Of Relief, But What's Next?
